HP
LGND icon

Hikari Power’s Ligand Pharmaceuticals LGND Stock Holding History

Hikari Power’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-16,030
Closed -$1.06M – 100
2017
Q1 		$1.06M Hold
16,030
– – 0.15% 46
2016
Q4 		$1.02M Buy
+16,030
New +$1.01M 0.14% 46

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Hikari Power's LGND Position: Q2 2017 in Review

Hikari Power sold out of Ligand Pharmaceuticals (LGND) in Q2 2017, closing a stake of 16,030 shares — an estimated $1.06M sold.

Hikari Power first reported a position in LGND in Q4 2016 and held it in 2 quarters. The position peaked at $1.06M in Q1 2017. 266 funds tracked by Wall St. Rank hold LGND as of Q2 2017.

  • Hikari Power reported no remaining Ligand Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Hikari Power sold 16,030 Ligand Pharmaceuticals shares in Q2 2017, an estimated $1.06M.
  • Hikari Power first reported a position in Ligand Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Hikari Power's Ligand Pharmaceuticals position peaked at $1.06M in Q1 2017.
  • 266 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2017.

Based on Hikari Power's 13F filing for Q2 2017, filed 9 Aug 2017.